In AI answers, Merck is a name on industry lists, and the press story goes largely untold

This is a snapshot from 29 September 2026: 250 unbranded category questions put to ChatGPT, Claude, Gemini, Perplexity and Grok, 1,250 answers in all. Merck was named in 158 of them. Grok named it most often (48 of 250), while ChatGPT and Claude each named it in 25. The 12 answers supplied here are a sample of those 158.

Merck's visibility depended heavily on the kind of question. It showed up most in leadership questions (38%), then employer (27%) and sustainability (25%). It did not appear in value or service questions (0% each) and was thin on safety (5%) and reliability (9%). In the tagged data, most credits fall under "Not Substantive", meaning Merck was usually listed rather than described. A few were tagged Financial Performance, Labour & Workplace, and Safety & Compliance.

In the sampled answers Merck usually appears as one name in a longer list. It is in oncology pipeline lists from ChatGPT and Gemini, a revenue list from ChatGPT, and a list of companies with cancer patient assistance programs from Claude. Claude's R&D-spend answer is the sharpest framing, leading with Merck on absolute dollars. Gemini's oncology answer tied Merck to Keytruda and to diversification ahead of patent expirations. Gemini also listed Merck among companies that testified to Congress on list prices and rebates.

Grok's answer on safety withdrawals gave Merck's entry as rofecoxib (Vioxx), withdrawn worldwide in 2004, and noted that it "led to major litigation". That is one answer to one question, but it shows an old episode can be the lead detail when the question is about safety.

PeakMetrics' news index logged 20,731 Merck mentions in the last 30 days, 1,998 of them with Merck in the headline. That is the highest mention count of the 15 peers in this dataset, ahead of Amgen (20,317), Pfizer (19,027) and Eli Lilly (19,681).

The recent headlines are about a Phase 2b/3 trial meeting its primary endpoint, whether Merck stock is pricing in a post-Keytruda future too soon, a $400 million purchase of KRAS rights, a veterinary product label (EXZOLT), and the Merck Foundation's fertility care campaign.

Press volume and AI presence do not track each other here. Merck has the most news mentions among these peers but ranks fifth in how many answers named it. Johnson & Johnson (192), UnitedHealth Group (179), CVS Health (174) and Pfizer (174) each appeared more often, on far less news in the case of the two health-services names.

The stories also differ. The press is currently about the pipeline after Keytruda, a trial readout and deal-making. The answers mostly place Merck as a large, established name in category lists, with R&D spend and the Keytruda-anchored oncology business as the specific hooks. The Merck Foundation campaign appears in the press sample, but none of the sampled answers surfaced it. Meanwhile an older safety episode did surface in an answer.

This is one snapshot. Live answers vary between runs, so these are not rankings.

Check which question types Merck is missing from. In this snapshot, value, service, safety and reliability questions returned little or nothing, while leadership questions returned the most. A comms team could test whether its recent news, such as trial results and diversification deals, shows up in pipeline answers, or whether the answers keep repeating the Keytruda-anchored framing.

Watch how each assistant handles safety and pricing questions. The Vioxx entry in Grok's answer and Gemini's congressional testimony list show that older episodes can define Merck's presence in those categories. Because assistants differ sharply in how often they name Merck, track the five separately rather than as one pooled number.